eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
.this website uses cookies. using this website means you are okay with this but you can find out more and learn how to manage your cookie choices
. it also provides 85 per cent accurate prediction results than current methods.
.